Ipsen.com

Ipsen – improving patient health outcomes

WebWHAT WE DO. Improving people’s lives and health outcomes by focusing on areas of high unmet medical need, we are accelerating our momentum and rapidly …

Actived: 5 days ago

URL: https://www.ipsen.com/us/

We focus on improving the health outcomes of people living

WebCollaborating with like-minded partners, we are focused on developing first- and best-in-class treatments for people living with cancer who have high unmet medical need. Our …

Category: Cancer, Medical Go Health

Ipsen: who we are

WebWe are a global, mid-size pharmaceutical company focusing on areas of high unmet medical need. Focus. Together. For patients and society. ABOUT IPSEN. Our team of over 5,000 …

Category: Medical Go Health

Ipsen puts patients first

WebIpsen Clinical Trials. Ipsen conducts first-in-the-world clinical trials to take science forward together. Our global network of healthcare professionals helps us test new treatments …

Category: Health Go Health

Closing Gaps in Cancer Care – Together

WebClosing Gaps in Cancer Care – Together. Midsize with a Big Vision. - 31 January 2024 - 4 mins read. Dr. Mónica de Abadal, Head of Medical Affairs, North …

Category: Cancer, Medical Go Health

U.S. FDA approves Bylvay® for patients living with

WebAbout Bylvay® (odevixibat) Bylvay is a potent, once-daily, non-systemic IBATi that acts locally in the small intestine and has minimal systemic exposure. It is …

Category: Health Go Health

US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the …

Web“The first treatment for FOP has been proven to reduce the volume of new abnormal bone growth, which may result in better health outcomes for people living with FOP.” The FDA …

Category: Health Go Health

Dr. James A Levine

WebDr Levine. Dr Levine, M.D., Ph.D., is currently Professor of Endocrinology and Nutrition Research at the Mayo Clinic in Scottsdale, Arizona. Having trained in clinical nutrition as …

Category: Nutrition Go Health

Primary Biliary Cholangitis: The Power of Patient Reported Outcomes

WebThe first is the risk of progression to cirrhosis, and the other is symptoms and quality of life.”. – Professor David Jones. Primary Biliary Cholangitis, or PBC, is a rare, …

Category: Health Go Health

Ipsen: who we are

WebWe are a global, mid-size pharmaceutical company focusing on areas of high unmet medical need. Focus. Together. For patients and society. ABOUT IPSEN. Our team of over 5,000 …

Category: Medical Go Health

Ipsen puts patients first

WebPutting patients first. At Ipsen, patients motivate every decision we make. We work side-by-side with them to improve their lives and deliver outcomes that make a meaningful …

Category: Health Go Health

Ipsen – improving patient health outcomes

WebIpsen focuses on three key therapeutic areas, leveraging all our resources to help patients with unmet medical needs. Oncology. We focus on improving the health outcomes of …

Category: Medical Go Health

Health Canada approves Ipsen’s Sohonos (palovarotene capsules) …

WebPARIS, France, 24 January 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the Health Canada approval of SohonosTM (palovarotene capsules), an oral selective …

Category: Health Go Health

Ipsen Annual Report Innovation for Patient Care

WebIpsen’s 2022 Integrated Annual Report. In 2022 we further accelerated Ipsen’s momentum, sustained our growth and made a positive impact for patients and society. Download the …

Category: Health Go Health

At Ipsen, we carefully build our robust portfolio

WebOur 2022 milestones include further countries approving Cabometyx ® (cabozantinib) in combination with nivolumab in a new indication in patients with previously untreated, …

Category: Health Go Health

Ipsen development pipeline investing in R&D for patient care

WebOur R&D strategy for a thriving product pipeline. As a global biopharmaceutical company with a focus on innovation and specialty care, Ipsen is building a strong and sustainable …

Category: Health Go Health

Health Canada approves Ipsen’s Sohonos (palovarotene

WebPARIS, France, 24 January 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the Health Canada approval of Sohonos (palovarotene capsules), an oral selective …

Category: Health Go Health

Ipsen receives Complete Response Letter for palovarotene, an

WebThe CRL is related to the U.S. FDA’s previous request for additional information on palovarotene clinical trial data; Ipsen anticipates responding to the …

Category: Health Go Health

Ipsen presents strong full-year 2021 results and enters into

WebStrong 2021 financial performance with total-sales growth of 12.3% at CER 1 (growth of 10.7% as reported) and a core operating margin of 35.2% (IFRS operating …

Category: Health Go Health

Ipsen receives CHMP negative opinion, following re-examination …

WebPalovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease with an estimated …

Category: Medicine Go Health

Want better care

WebNext. Want better care? Show up like a boss. Improving Lives. - 12 March 2024 - 3 mins read. Liz Kalina, Vice President of North America Corporate Affairs and …

Category: Health Go Health